1. Introduction

Lab-grown organ commerce refers to the commercial development, manufacture, licensing, distribution, sale, and transplantation of organs or organ-like biological structures produced using biotechnology. These may be developed from stem cells, a patient's own cells, tissue engineering, organoids, or biofabrication techniques.

The legal question is whether an organ grown in a laboratory should be treated as a prohibited human organ for sale, a regulated medical product, a patented technological invention, or a combination of these categories.

The central legal distinction is between selling a human organ obtained from a person and charging for a laboratory-manufactured biological product. Traditional organ-trafficking laws were principally designed to prevent exploitation and the buying and selling of human organs. Their application to fully lab-grown, transplantable organs is not always expressly settled.

In India, the main starting point is the Transplantation of Human Organs and Tissues Act, 1994 (THOTA), together with medicines regulation, medical-device requirements where applicable, clinical-trial rules, intellectual-property law, and general consumer-protection and liability principles.

India Code+1

This discussion focuses primarily on Indian law, with comparative references to the United States. It distinguishes established law from legal questions that remain unresolved.

2. Meaning and types of lab-grown organs

SUNUM - Bioprinting Laboratory

A. Tissue-engineered organs

Biological structures created by growing cells on scaffolds or other supporting materials. Examples include engineered skin, cartilage, and experimental vascular tissue.

CMU's Online Graduate Certificate in 3D Bioprinting & Biofabrication - Online Education - Carnegie Mellon University

B. 3D-bioprinted organs

Structures produced by depositing cell-containing biomaterials in a controlled pattern. Fully functional, transplantable solid organs remain a significant scientific challenge.

3D Cell Culture Primer: Freezing, Culturing, and Measuring Organoids | Corning

C. Organoids

Small, simplified, three-dimensional models of organs grown from cells. They are often used in research and drug testing rather than transplantation.

GMP Labor / Core Facilities Forschungsmanagement

D. Patient-specific engineered organs

Biological constructs made using a patient's own cells. These raise questions concerning consent, genetic information, manufacturing rights, quality control, and ownership.

The precise legal classification depends on what is being sold. A research organoid, a living tissue implant, a genetically modified construct, and a fully functional replacement organ may fall under different regulatory regimes.

3. Legal framework in India

A. Transplantation of Human Organs and Tissues Act, 1994

The Transplantation of Human Organs and Tissues Act, 1994 is the principal Indian statute governing organ transplantation and the prevention of commercial dealings in human organs and tissues.

India Code+1

The most relevant provisions are:

The statutory scheme and relevant provisions can be examined through the official India Code legislation record.

India Code+1

Application to lab-grown organs: Section 19 prohibits specified transactions involving payment for the supply of human organs, including certain offers and arrangements for paid supply. However, whether a wholly laboratory-created organ falls within the statutory definition of a human organ requires careful interpretation of the statutory language and the particular product.

The Act should not automatically be treated as either prohibiting every commercial lab-grown organ or exempting every engineered organ from regulation.

B. Section 19: Commercial dealings

Section 19 is particularly important because it targets the commercial supply chain surrounding human organs.

Potentially prohibited conduct includes:

Paying someone for supplying a legally covered human organ.

Offering a covered human organ for payment.

Recruiting a person willing to supply an organ for payment.

Negotiating arrangements involving payment for such supply.

The exact statutory elements must be established in any prosecution.

IndiaCode+1

Consider three examples:

A kidney taken from a living person and sold: This falls squarely within the type of conduct targeted by organ-trafficking legislation.

A laboratory grows a kidney-like construct using cells and biomaterials: Whether the construct is legally a human organ under THOTA is an unresolved classification question; regulatory approval and other legal obligations may still apply.

A company charges for manufacturing a patient's engineered tissue: A genuine manufacturing fee is distinguishable from payment for an illegally supplied human organ. The fee's label alone, however, cannot legalise an otherwise prohibited transaction.

C. Drugs and clinical-product regulation

A lab-grown organ intended for implantation may also be subject to India's drug, biologics, clinical-trial, or medical-device framework, depending on its composition, manufacturing process, intended use, and regulatory classification.

Relevant legislation and rules may include:

The Drugs and Cosmetics Act, 1940.

The New Drugs and Clinical Trials Rules, 2019.

Applicable medical-device regulations.

Clinical-research ethics requirements and institutional approvals.

The precise classification of a complex living organ construct cannot safely be determined from its name alone. Manufacturers should seek a formal regulatory assessment before clinical use or commercial distribution.

4. Important case laws

There is no established reported Indian appellate precedent squarely deciding whether a fully lab-grown, transplantable human organ can be sold as a manufactured product under THOTA. The following cases provide relevant principles by analogy.

Case 1: Amar Singh Bhatia & Anr. v. Sir Ganga Ram Hospital & Ors. (Delhi High Court, 2024)

Decision dated 4 January 2024 · W.P. (C) 3590/2020

Legal issue: How should the transplantation legislation be interpreted while protecting patients and preventing commercial exploitation?

Significance: The Delhi High Court examined the regulatory framework under the 1994 Act and emphasised that the statute regulates transplantation and prohibits commercial dealings in human organs. The judgment also addressed the need for effective implementation of the statutory approval system.

Indian Kanoon+1

Application to lab-grown organs: The case supports a distinction between lawful transplantation and prohibited commercial organ trafficking. It does not, however, decide whether a manufactured biological organ falls within the statutory definition of a human organ.

Case 2: Ajay Mittal & Others v. Union of India & Another (Punjab and Haryana High Court, 2022)

Decision dated 6 December 2022 · CWP No. 26361 of 2022

Legal issue: The regulation of organ transplantation and the prevention of commercial transactions.

Significance: The Court discussed the social and ethical concerns underlying the transplantation legislation, including exploitation arising from socioeconomic inequality. It explained that the purpose of the Act is to regulate transplantation and prevent commercial monetary transactions, rather than to prohibit transplantation itself.

Live Law

Application to lab-grown organs: The reasoning highlights the importance of preventing exploitation. A commercial market in engineered organs would therefore need safeguards against coercion, inequitable access, deceptive marketing, and unlawful sourcing of human cells. These are applications of the case's general principles, not findings specifically about lab-grown organs.

Case 3: Dr. Jyoti Bansal v. State of Rajasthan (Rajasthan High Court, 2024)

Decision dated 30 May 2024 · S.B. Crl. M.P. 2715/2024

Legal issue: Whether criminal proceedings concerning alleged commercial kidney-transplant arrangements should be quashed while the investigation was ongoing.

Significance: The High Court declined to quash proceedings where the allegations included paid donors, intermediaries, and financial links connected with a suspected transplant racket. The case illustrates how evidence of payment arrangements and intermediary involvement can support continued investigation under Section 19.

IndiaCode

Application to lab-grown organs: A company could not avoid scrutiny merely by describing a transaction as biotechnology commerce if the underlying arrangement involved the unlawful purchase or supply of human organs. Whether Section 19 applies would still depend on the actual facts and the legal classification of the material being supplied.

Case 4: Flynn v. Holder, 684 F.3d 852 (9th Cir. 2012)

Jurisdiction: United States Court of Appeals for the Ninth Circuit.

Legal issue: Whether federal legislation prohibiting the purchase of human organs also prohibited compensation for certain peripheral-blood stem-cell donations.

Significance: The Ninth Circuit held that the proposed compensation scheme for peripheral-blood stem-cell donors was not barred by the National Organ Transplant Act as applied in that case. The distinction between the statutory treatment of bone-marrow donations and peripheral-blood stem-cell collection was central to the analysis.

The US statute, 42 U.S.C. § 274e, prohibits acquiring, receiving, or transferring covered human organs for valuable consideration for transplantation, subject to statutory exceptions.

THE PUBLIC HEALTH AND WELFARE+1

Application to lab-grown organs: The case demonstrates that the precise statutory definition of the biological material matters. It does not establish that fully lab-grown organs are freely saleable, nor does it determine the interpretation of Indian legislation.

5. Comparative legal position: India and the United States

India

Statutory interpretation required

THOTA expressly targets commercial dealings in covered human organs and tissues. A wholly engineered organ presents a classification question, while separate product-safety and clinical-use requirements may apply.

India Code+1

United States

The National Organ Transplant Act prohibits certain transfers of covered human organs for valuable consideration. Separately, the FDA regulates many cell, tissue, and regenerative-medicine products according to their characteristics and intended use. The rules for vascularized human organ transplantation are not identical to those for other tissue-engineered products.

LII / Legal Information Institute+2

The US FDA's official materials explain that some regenerative-medicine products require premarket review, while qualifying human cell and tissue products may be regulated under a different pathway. These classifications depend on the applicable statutory and regulatory criteria.

FDA+1

6. Ownership and intellectual-property rights

The commercial status of lab-grown organs raises several separate ownership questions.

A. Ownership of the manufactured organ

A company may own manufacturing equipment, materials, and certain contractual or intellectual-property rights. That does not necessarily establish unrestricted ownership of every living construct produced using human cells.

The law must distinguish between ownership of a physical product, rights in the underlying biological material, and a person's interests in their body and genetic information.

B. Patent protection

Patents may potentially protect qualifying inventions relating to:

Bioprinting processes and specialised equipment.

Novel biomaterials and scaffolds.

Methods of manufacturing engineered tissue.

Certain engineered cell technologies.

Technical improvements that satisfy the applicable patentability requirements.

In India, the Patents Act, 1970, including Sections 3(c) and 3(j), imposes relevant exclusions concerning discoveries of living things or non-living substances occurring in nature and certain plants, animals, biological processes, and products. The applicability of these exclusions depends on the claimed invention and its precise technical characteristics.

A patent on a manufacturing process does not itself authorise an otherwise unlawful organ sale or an unapproved medical procedure.

C. Consent and use of patient-derived cells

Where a patient's cells are used to produce an organ, the legal framework should clearly address:

Consent to collection and laboratory use.

Secondary research and commercial use.

Storage, transfer, and security of biological samples.

Handling of genetic and other sensitive health information.

Responsibility for contamination, defects, or manufacturing failures.

The legal consequences may differ where cells are donated voluntarily, collected during medical treatment, or obtained through an agreement specifically intended for commercial production.

7. Liability and consumer protection

Commercial production creates risks that traditional organ-donation rules alone may not address.

Liability should be allocated according to the conduct of the manufacturer, laboratory, treating clinician, hospital, and distributor. Contractual terms cannot necessarily exclude mandatory statutory obligations or liability for unlawful conduct.

8. Ethical and constitutional concerns

A legal market in engineered organs could reduce reliance on living donors and potentially expand the supply of transplantable material. However, it also raises substantial ethical questions.

Human dignity: The law should distinguish the commercial sale of a manufactured therapeutic product from treating the human body itself as an unrestricted commodity.

Equality and access: If engineered organs are extremely expensive, access may be limited to wealthy patients. Public policy may need to address fair allocation, insurance coverage, and access for medically eligible patients.

Safety and informed consent: Patients must receive accurate information about uncertainty, rejection, failure rates, long-term risks, and alternatives.

Genetic privacy: Patient-derived manufacturing may reveal information about inherited characteristics and biological relatives. Data collection and use must comply with applicable privacy and health-information laws.

Intergenerational effects: Some advanced biological interventions could have effects that persist beyond the immediate recipient, requiring additional ethical and regulatory scrutiny where relevant.

These concerns support a risk-based regulatory system; they do not, by themselves, establish that every commercial transaction involving a lab-grown organ is illegal.

9. Proposed regulatory framework for lab-grown organ commerce

A comprehensive framework should address at least the following matters:

Classification: Define laboratory-grown organs, tissue-engineered products, organoids, and other biological constructs separately where appropriate.

Manufacturing authorisation: Establish quality, traceability, sterility, and validated manufacturing requirements.

Clinical approval: Require suitable evidence of safety and efficacy before routine transplantation.

Commercial safeguards: Distinguish permissible manufacturing and treatment charges from prohibited payments for human organs.

Consent and privacy: Establish rules for obtaining, storing, and using patient-derived cells and associated data.

Liability and insurance: Specify responsibility for manufacturing defects, adverse outcomes, recalls, and long-term monitoring.

Fair access: Develop transparent allocation policies and appropriate safeguards against discriminatory treatment.

Cross-border controls: Clarify import, export, transport, and jurisdictional responsibilities for engineered biological products.

International standards for tissue-engineered medical products can assist with manufacturing and quality-control design, but standards do not replace binding national legislation.

ISO+1

10. Conclusion

The legal status of lab-grown organ commerce lies at the intersection of organ-transplantation law, biotechnology regulation, intellectual property, consent, product liability, and medical ethics.

Under Indian law, THOTA clearly prohibits specified commercial dealings in human organs and regulates transplantation. Whether its prohibition extends to a fully laboratory-created organ depends on the statutory definitions and the facts; the issue should not be treated as conclusively resolved by cases concerning conventional organ trafficking.

The most defensible legal approach is to distinguish the sale of a manufactured biological product from the purchase of a human organ, while requiring appropriate safety approval, lawful sourcing, informed consent, traceability, and accountability.

Research note: This is a legal overview, not a formal legal opinion. For a proposed commercial venture or clinical programme, the specific product, cell source, manufacturing process, and intended use should be reviewed under the legislation and regulatory guidance in force at the relevant time.